TY - JOUR
T1 - New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer
AU - Ettinger, David S.
N1 - Funding Information:
From The Johns Hopkins Oncology Center, Baltimore, MD. Dr Ettinger has served as a consultant and speaker for and has received research grant support from Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline. Address reprint requests to David S. Ettingel-, MD, Bunting Blaustein Cancer Research Building, 1650 Orleans St, Baltimore, MD 21231-1000. Copyright 0 2001 by W.B. Saunders Company 0093x7754/01/2802-0405$3.5.00/O doi:10.1053/sonc.2001.25742
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2001
Y1 - 2001
N2 - To improve the survival of patients with small cell lung cancer, there is a need for new and effective agents to treat this disease. These agents include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin. In previously untreated small cell lung cancer patients the response rate for these effective drugs ranges from 27% to 79%. Median survival ranges from 6.6 to 12 months. The major toxicity for these agents is leukopenia. Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer.
AB - To improve the survival of patients with small cell lung cancer, there is a need for new and effective agents to treat this disease. These agents include paclitaxel, docetaxel, topotecan, irinotecan, vinorelbine, gemcitabine, and amrubicin. In previously untreated small cell lung cancer patients the response rate for these effective drugs ranges from 27% to 79%. Median survival ranges from 6.6 to 12 months. The major toxicity for these agents is leukopenia. Studies are ongoing to evaluate the efficacy of combination chemotherapy using new agents either together or with other known effective drugs for the treatment of small cell lung cancer.
UR - http://www.scopus.com/inward/record.url?scp=0034909054&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034909054&partnerID=8YFLogxK
U2 - 10.1016/s0093-7754(01)90075-2
DO - 10.1016/s0093-7754(01)90075-2
M3 - Short survey
C2 - 11479894
AN - SCOPUS:0034909054
SN - 0093-7754
VL - 28
SP - 27
EP - 29
JO - Seminars in oncology
JF - Seminars in oncology
IS - 2 SUPPL. 4
ER -